Search

Your search keyword '"Dursun, Bengü"' showing total 10 results
Start Over Author "Dursun, Bengü"
10 results on '"Dursun, Bengü"'

1. The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

Author

Özyurt, Neslihan, Alkan, Ali, Gülbağcı, Burcu, Seyyar, Mustafa, Aydın, Esra, Şahbazlar, Mustafa, Türker, Mehmet, Kınıkoğlu, Oğuzcan, Yerlikaya, Tahir, Dinç, Gülhan, Aytaç, Ali, Kalkan, Ziya, Ebinç, Senar, Gültürk, İlkay, Keskinkılıç, Merve, İşleyen, Zehra Sucuoğlu, Çağlayan, Dilek, Türkel, Alper, Aydın, Esra, Şakalar, Teoman, Sekmek, Serhat, Yıldırım, Nilgün, Koçak, Sinem, Okutur, Kerem, Özveren, Ahmet, Dursun, Bengü, Kitaplı, Sait, Eren, Orhan Önder, Beypınar, İsmail, Hacıbekiroğlu, İlhan, Çabuk, Devrim, Karaman, Elanur, Acar, Ömer, Paydaş, Semra, Eryılmaz, Melek Karakurt, Demir, Bilgin, Oruç, Zeynep, Yılmaz, Mesut, Biricik, Fatih Selçuk, Salim, Derya Kıvrak, Tanrıverdi, Özgür, and Doğan, Mutlu

Published
2024
Full Text
View/download PDF

2. The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer in male patients: a Turkish oncology group (TOG) study

Author

Yıldırım, Hasan Çağrı, Kutlu, Yasin, Mutlu, Emel, Aykan, Musa Barış, Korkmaz, Mustafa, Yalçın, Selim, Şakalar, Teoman, Celayir, Özde Melisa, Kayıkçıoğlu, Erkan, Aslan, Ferit, Hafızoğlu, Emre, Altıntaş, Yunus Emre, Keskinkılıç, Merve, Chalabiyev, Elvin, Çelebi, Abdussamet, Dursun, Bengü, Kapar, Caner, Özen, Miraç, Acar, Ömer, Dülgar, Özgecan, Kut, Engin, Biter, Sedat, Kus, Fatih, Almuradova, Elvina, Erdoğan, Atike Pınar, Saray, Seray, Güven, Deniz Can, Şimşek, Eda Tanrıkulu, Üskent, Necdet, Kemal, Yasemin, Çakar, Burcu, Açıkgöz, Özgür, Kılıçkap, Saadettin, and Aksoy, Sercan

Published
2024
Full Text
View/download PDF

3. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

Author

Guven, Deniz Can, primary, Aykan, Musa Baris, additional, Muglu, Harun, additional, Bayram, Ertugrul, additional, Helvaci, Kaan, additional, Dursun, Bengü, additional, Celayir, Melisa, additional, Chelebiyev, Elvin, additional, Nayir, Erdinc, additional, Erman, Mustafa, additional, Sezer, Ahmet, additional, Urun, Yuksel, additional, Demirci, Umut, additional, Er, Ozlem, additional, Disel, Umut, additional, Bilici, Ahmet, additional, Arslan, Cagatay, additional, Karadurmus, Nuri, additional, and Kilickap, Saadettin, additional

Published
2023
Full Text
View/download PDF

4. Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group

Author

Ünal, Çağlar, primary, Azizy, Abdulmunir, additional, Karabulut, Senem, additional, Taştekin, Didem, additional, Akyıldız, Arif, additional, Yaşar, Serkan, additional, Yalçın, Şuayib, additional, Çoban, Eyüp, additional, Evrensel, Türkkan, additional, Kalkan, Ziya, additional, Oruç, Zeynep, additional, Derin, Sümeyra, additional, Turna, Zeynep Hande, additional, Bayram, Doğan, additional, Köş, Fahriye Tuğba, additional, Şendur, Mehmet Ali Nihat, additional, Sever, Nadiye, additional, Ercelep, Özlem, additional, Seyyar, Mustafa, additional, Kefeli, Umut, additional, Uygun, Kazım, additional, Özçelik, Melike, additional, Ön, Sercan, additional, Şanlı, Ulus Ali, additional, Canaslan, Kübra, additional, Ünek, İlkay Tuba, additional, Yücel, Kadriye Bir, additional, Özdemir, Nuriye, additional, Yazıcı, Ozan, additional, Güzel, Halil Göksel, additional, Salim, Derya Kıvrak, additional, Göksu, Sema Sezgin, additional, Tatlı, Ali Murat, additional, Ordu, Çetin, additional, Selvi, Oğuzhan, additional, Sakin, Abdullah, additional, Büyükbayram, Mehmet Emin, additional, Dursun, Bengü, additional, Ürün, Yüksel, additional, Arak, Hacı, additional, Ağdaş, Gözde, additional, Uğraklı, Muzaffer, additional, Hendem, Engin, additional, Eryılmaz, Melek Karakurt, additional, Bilgin, Burak, additional, Topçu, Atakan, additional, Şimşek, Melih, additional, Büyükşimşek, Mahmut, additional, Akay, Büşra, additional, Erdal, Gülçin Şahingöz, additional, Karataş, Fatih, additional, Alan, Özkan, additional, Çağlayan, Melek, additional, Kahvecioğlu, Fatma Akdağ, additional, Demirci, Ayşe, additional, Paksoy, Nail, additional, Çetin, Bülent, additional, Gümüş, Mahmut, additional, Ak, Naziye, additional, Aydınalp, Yasemin, additional, Paydaş, Semra, additional, Güven, Deniz Can, additional, Kılıçkap, Saadettin, additional, and Sağlam, Sezer, additional

Published
2023
Full Text
View/download PDF

5. The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study.

Author

Guven, Deniz Can, Aykan, Musa Baris, Muglu, Harun, Bayram, Ertugrul, Helvaci, Kaan, Dursun, Bengü, Celayir, Melisa, Chelebiyev, Elvin, Nayir, Erdinc, Erman, Mustafa, Sezer, Ahmet, Urun, Yuksel, Demirci, Umut, Er, Ozlem, Disel, Umut, Bilici, Ahmet, Arslan, Cagatay, Karadurmus, Nuri, and Kilickap, Saadettin

Subjects
IMMUNE checkpoint inhibitors, MERKEL cell carcinoma, IMMUNOTHERAPY, COMBINATION drug therapy, PROGRESSION-free survival, GERM cell tumors
Abstract

Introduction: The advances in immune checkpoint inhibitors (ICIs) were relatively slow in rare tumors. Therefore, we conducted a multi-center study evaluating the efficacy of ICI monotherapy and the combination of ICIs with chemotherapy (CT) in patients with advanced rare tumors. Methods: In this retrospective cohort study, we included 93 patients treated with ICIs for NCI-defined rare tumors from the 12 cancer centers in Turkey. The primary endpoints were the overall response (ORR) and disease control rate (DCR). Results: The cohort's median age was 56, and 53.8% of the patients were male. The most frequent diagnosis was sarcoma (29%), and 81.7% of the patients were previously treated with at least one line of systemic therapy in the advanced stage. The ORR and DCR were 36.8% and 63.2%, respectively. The germ cell tumors had the lowest ORR (0%), while the Merkel cell carcinoma had the highest ORR to ICIs (57.1%). Patients treated with ICI+ICI or ICI plus chemotherapy combinations had higher ORR (55.2% vs. 27.6%, p=0.012) and DCR (82.8% vs. 53.4%, p=0.008). The median OS was 13.47 (95% CI: 7.79–19.15) months, and the six and 12- month survival rates were 71% and 52%. The median duration of response was 16.59months, and the 12-month progression-free survival rate was 66% in responders. The median time-to-treatment failure was 5.06months (95% CI: 3.42– 6.71). Three patients had high-grade irAEs with ICIs (grade 3 colitis, grade 3 gastritis, and grade 3 encephalitis in one patient each). Conclusion: We observed over 30% ORR and a 13-month median OS in patients with rare cancers treated with ICI monotherapy or ICI plus CT combinations. The response rates to ICIs or ICIs plus CT significantly varied across different tumor types. Responding patients had over 2 years of survival, highlighting a need for further trials with ICIs for patients with rare tumors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Comparison of Adjuvant Modified FOLFIRINOX with Other Adjuvant Chemotherapies in Resected Pancreatic Adenocarcinoma: Real-life Data

Author

Erol, Cihan, primary, Hafızoğlu, Emre, additional, Aykan, Musa Barış, additional, Güven, Deniz Can, additional, Dursun, Bengü, additional, Hızal, Mutlu, additional, Kahraman, Seda, additional, Şener Dede, Didem, additional, Akıncı, Muhammed Bülent, additional, Karadurmuş, Nuri, additional, Ürün, Yüksel, additional, Algın, Efnan, additional, Yalçın, Şuayib, additional, Yalçın, Bülent, additional, and Şendur, Mehmet Ali Nahit, additional

Published
2023
Full Text
View/download PDF

7. Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study

Author

Yıldırım, Hasan Çağrı, primary, Mutlu, Emel, additional, Chalabiyev, Elvin, additional, Özen, Miraç, additional, Keskinkılıç, Merve, additional, Ön, Sercan, additional, Çelebi, Abdussamet, additional, Dursun, Bengü, additional, Acar, Ömer, additional, Kahraman, Seda, additional, Aykan, Musa Barış, additional, Kaman, Ömür, additional, Doğan, Akif, additional, Erdoğan, Atike Pınar, additional, Melisa Celayir, Özde, additional, Günenç, Damla, additional, Güven, Deniz Can, additional, Vedat Bayoğlu, İbrahim, additional, Yavuzşen, Tuğba, additional, Hacıbekiroğlu, İlhan, additional, İnanç, Mevlüde, additional, Kılıçkap, Saadettin, additional, Yalçın, Şuayib, additional, and Aksoy, Sercan, additional

Published
2022
Full Text
View/download PDF

8. Seasonal Influenza and Pneumococcal Vaccination Rates Among Patients with Cancer in COVID-19 Pandemic: A Cross-Sectional Study

Author

YEKEDÜZ, Emre, primary, KÖKSOY, Elif Berna, additional, YAZGAN, Satı Coşkun, additional, AKBIYIK, Ilgın, additional, BALLI, Sevinç, additional, KAVAK, Engin Eren, additional, KALACI, Ender, additional, DURSUN, Bengü, additional, KUBİLAY TOLUNAY, Pınar, additional, GÜRBÜZ, Mustafa, additional, AKBULUT, Hakan, additional, DEMİRKAZIK, Ahmet, additional, ÇAY ŞENLER, Filiz, additional, UTKAN, Güngör, additional, and ÜRÜN, Yüksel, additional

Published
2021
Full Text
View/download PDF

10. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer.

Author

Yildirim HC, Buyukkor M, Kavgaci G, Celik BŞ, Yucel KB, Dursun B, Chalabiyev E, Yilmaz F, Yildirim SS, Kus F, Tay F, Gecgel A, Koksal B, Guven DC, Yazici O, Urun Y, Ozet A, Gokmen E, Oksuzoglu B, and Aksoy S

Subjects
Humans, Female, Retrospective Studies, Middle Aged, Aged, Protein Kinase Inhibitors therapeutic use, Protein Kinase Inhibitors pharmacology, Adult, Progression-Free Survival, Receptors, Estrogen metabolism, Breast Neoplasms drug therapy, Breast Neoplasms pathology, Breast Neoplasms mortality, Receptor, ErbB-2 metabolism, Receptor, ErbB-2 antagonists & inhibitors, Cyclin-Dependent Kinase 4 antagonists & inhibitors, Cyclin-Dependent Kinase 6 antagonists & inhibitors
Abstract

The fact that the human epidermal growth factor receptor 2 (HER2)-low group, historically classified as HER2 negative in breast cancer histology, benefited from HER2-targeted treatments similarly to the HER2-positive group indicates that this group has a distinct histology from the HER2-0 group. The effectiveness of cyclin-dependent kinase 4/6 inhibitors, which are the standard first-line treatment for hormone receptor-positive, HER2-negative advanced breast cancer, in this newly defined histological subgroup remains a topic of debate. In our study, we examined the impact of HER2 status on the efficacy of CDK4/6 inhibitors. Our study is a retrospective, multicenter, real-world data analysis. One hundred sixty patients were included in the study. The relationship between HER2 status and other clinical-pathological features, as well as progression-free survival, was examined. Median follow-up was 20.33 ± 0.98 months. The mPFS could not be reached. All patients exhibited positive estrogen receptor expression. Among the patients, 111 (69.4%) were categorized as HER2-0, and 49 (30.6%) as HER2-low. The 24-month progression-free survival rates were similar between HER2-0 and HER2-low patients (60.6% vs 65.3%, hormone receptor: 1.18, CI: 0.67-2.20, P = .554). We established that the mPFS achieved with cyclin-dependent kinase 4/6 inhibitors as a first-line therapy for patients with advanced breast cancer is unaffected by HER2 status., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results